NOVATO, Calif. (AP) – BioMarin Pharmaceutical Inc. said on Nov. 29 the U.S. Food and Drug Administration approved the expansion of a manufacturing facility where the company makes several of its drugs.
The company said the manufacturing facility now has the capacity to produce $1 billion in products, twice its previous capacity. BioMarin received approval to make its drug Aldurazyme at the facility in 2003 and Naglazyme in 2005. Both drugs treat an inherited metabolic disease that can cause tissue damage and mental retardation.
The facility is also producing some of Biomarin’s drug candidates, and the company said it will use the expanded facility to make a drug designed to treat Morquio A Syndrome if regulators approve the drug.
Earlier this year, BioMarin moved to expand its manufacturing capacity by buying a Pfizer Inc. facility in Cork, Ireland.
The Associated Press